FeesSafety
Pluang+

Gold and Bitcoin rebound as Japan's core inflation hits 2.1%, yen weakens, and oil prices rise above $100.

Market News
23 Oct 2026
Tokenpost
View Source
Neutral
Gold and Bitcoin rebound as Japan's core inflation hits 2.1%, yen weakens, and oil prices rise above $100.

Gold and Bitcoin recovered from overnight losses in Asian trading after Japan's core inflation rose to 2.1% in September, surpassing the Bank of Japan's 2% target for the first time in nine months. The yen weakened slightly against the dollar, retreating from a one-month high amid risk-off trading conditions. Meanwhile, oil prices climbed above $100 a barrel, with West Texas Intermediate and Brent crude futures rising steadily. These movements reflect growing inflation concerns and market reactions to currency and commodity shifts.

Bitcoin and Gold market context shows positive momentum among cryptocurrencies on Pluang. As of Oct 24, 2026 02:31 WIB, 36 of 50 major cryptocurrencies rose. Notable movers include LUNC at Rp0,832 (+2.50%), ETC at Rp141.197 (+2.19%), and FTM at Rp11.382 (-2.05%).

More News

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY plus daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...

Market News
Bullish
1 hour ago
CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

CHMP recommends approval of Johnson & Johnson's TALVEY® plus daratumumab for earlier treatment of relapsed multiple myeloma

The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...

Market News
Bullish
1 hour ago
CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

CHMP recommends approval of Johnson & Johnson's TALVEY® with daratumumab for earlier treatment of relapsed/refractory multiple myeloma.

The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...

Market News
Bullish
1 hour ago
Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea and Omico partner to accelerate biomarker-led cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...

Market News
Bullish
2 hours ago
Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea and Omico partner to speed biomarker-based cancer drug trials in Australia

Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App